Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Seer ( (SEER) ) has provided an update.
On April 13, 2026, Seer, Inc. confirmed that it had received a highly contingent, non-binding and unsolicited proposal from the Radoff-JEC Group to acquire all outstanding shares of its Class A common stock for $2.25 per share in cash plus a contingent value right. The board, working with independent financial and legal advisers, said it would carefully review the offer to determine the best course of action for the company and its shareholders, while stressing that no stockholder action is required at this time.
The Radoff-JEC Group also nominated three director candidates for election at Seer’s 2026 annual shareholder meeting, which has not yet been scheduled. Seer’s corporate governance and nominating committee will assess those nominees under its bylaws, and the board will present its formal recommendation in the forthcoming definitive proxy statement, signaling a potential proxy contest that could influence the company’s strategic direction and governance.
The most recent analyst rating on (SEER) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Seer stock, see the SEER Stock Forecast page.
Spark’s Take on SEER Stock
According to Spark, TipRanks’ AI Analyst, SEER is a Neutral.
The score is held back primarily by persistent losses and cash burn (despite improving margins) and bearish technicals with the stock trading below major moving averages. Conservative 2026 guidance and funding uncertainty add pressure, partially offset by low leverage, disciplined expense reductions, and management’s expectation of continued free-cash-flow improvement supported by its stated cash position.
To see Spark’s full report on SEER stock, click here.
More about Seer
Seer, Inc., listed on Nasdaq as SEER, operates in the proteomics industry, focusing on deep, unbiased protein analysis for research markets. The company’s Proteograph Product Suite combines proprietary engineered nanoparticles, automated instrumentation, consumables and analytical software to deliver large-scale, high-precision proteomic insights for research use only, not for diagnostic procedures.
Headquartered in Redwood City, California, Seer positions itself as a pioneer and trusted partner for advanced proteomic workflows. Its technology aims to overcome limitations of traditional proteomic methods, targeting pharmaceutical, biotechnology and academic researchers who require reproducible, high-throughput protein data.
Average Trading Volume: 266,009
Technical Sentiment Signal: Sell
Current Market Cap: $95.35M
Find detailed analytics on SEER stock on TipRanks’ Stock Analysis page.